Compare ONL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | TLSA |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 155.2M |
| IPO Year | 2021 | 2017 |
| Metric | ONL | TLSA |
|---|---|---|
| Price | $2.04 | $1.34 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 236.2K | 129.0K |
| Earning Date | 03-05-2026 | 05-06-2025 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $147,647,000.00 | N/A |
| Revenue This Year | $4.10 | N/A |
| Revenue Next Year | $3.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $0.73 |
| 52 Week High | $3.01 | $2.60 |
| Indicator | ONL | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 34.59 | 46.06 |
| Support Level | $1.96 | $1.27 |
| Resistance Level | $2.67 | $1.59 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 16.97 | 40.00 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.